Bioretec Oy (BRETEC) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Bioretec Oy €0.02, price €0.03, upside -28.6%, quality 19 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bioretec Oy for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range €0.0116 – €3.26 · the €0.0266 price screens above the €0.0190 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Bioretec Oy in your weekly email
Every Wednesday you see whether Bioretec Oy is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide.
Show more
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatment, osteotomy, arthrodesis, and bone graft surgery. It also provides ActivaScrew Cannulated that offers a range of fully threaded and partially threaded cannulated screws for fixation of fractures and osteotomies; ActivaScrew Interference, a tool for multiple uses regarding bone fractures, osteotomies, arthrodesesm, and bone grafts; ActivaScrew Interference TCP, a biocomposite interference screw; and RemeOs Screw, a magnesium screw implants. The company was formerly known as BCI Bioabsorbable Concepts Oy. The company was incorporated in 1998 and is headquartered in Tampere, Finland.
Stock analysis
Bioretec Oy (BRETEC) currently trades at €0.0266, while our model-based Fair Value estimate is €0.0190, 28.6% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Bioretec Oy reported revenue of €3.5M in FY2025 versus €2.0M in FY2021, a compound +15.2%/yr. Reported net income was −€9.5M in FY2025.
Key figures
Market cap €28.7M · EPS (TTM) €−0.0300 · Return on equity −4,861% · Return on assets (EBIT) −47.2% · Free cash flow −€10.3M · Net debt €506K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 98% below its 52-week high and 129% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −29%, BRETEC screens richer than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−22.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−128.4% (2020) → −246.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside−28.6% · Below median
Profitability
Return on assets0.0% · Below median
Operating margin (TTM)0.0% · Below median
Growth and dividend
Revenue growth0.0% · Below median
Balance sheet
Debt / equity0.01× · Below median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 9
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 11
HEALTH (low debt)99· sector 97
DIVIDEND (yield)0· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bioretec Oy Fair Value". https://www.fairvalue-calculator.com/stock/BRETEC
Frequently asked questions
Is Bioretec Oy (BRETEC) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of €0.0190 versus a price of €0.0266, about −29% upside (overvalued).
What is the fair value of BRETEC?
Our model-based fair value for Bioretec Oy is €0.0190 (as of Sep 27, 2026), built from audited fundamentals. The current price: €0.0266.
What is the quality score of BRETEC?
Bioretec Oy has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bioretec Oy (BRETEC)?
Our model-based price target is the fair value of €0.0190 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Bioretec Oy stock forecast for 2026?
Our models put fair value at €0.0190, about −29% upside versus a price of €0.0266 (overvalued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of Bioretec Oy (BRETEC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bioretec Oy it is €0.0190 per share (as of Sep 27, 2026), against a price of €0.0266. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Bioretec Oy stock overvalued or undervalued in 2026?
As of Sep 27, 2026, BRETEC trades above its calculated fair value: price €0.0266, fair value €0.0190, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BRETEC?
No. The price is what the market pays today (€0.0266); the fair value is what the company's own numbers justify (€0.0190). For Bioretec Oy the two are €0.0076 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bioretec Oy worth?
The market values Bioretec Oy at about €28.7M (market capitalisation, as of Sep 27, 2026). Per share that is €0.0266; our models calculate a fair value of €0.0190 per share.
How solid is the balance sheet of Bioretec Oy (BRETEC)?
Balance-sheet figures for Bioretec Oy (as of Sep 27, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 19/100, which measures business quality independently of the share price.
How far is BRETEC from its 52-week high?
Bioretec Oy trades at €0.0266, about 98% below its 52-week high of €1.53 and 129% above the low of €0.0116 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €0.0190 is for.
Which stocks are comparable to Bioretec Oy?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bioretec Oy stock attractive at the current price?
The data as of Sep 27, 2026: price €0.0266, calculated fair value €0.0190 (−29%), Quality Score 19/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BRETEC calculated?
We run Bioretec Oy through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.0190, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Bioretec Oy itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bioretec Oy (BRETEC)?
The closing price on Oct 2, 2026 was €0.0266. Our model-based fair value is €0.0190, about −29% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bioretec Oy right now?
Weak quality (19/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Bioretec Oy
How large is the market capitalisation of Bioretec Oy (BRETEC)?
The market capitalisation of Bioretec Oy is €28.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Bioretec Oy (BRETEC)?
Earnings per share at Bioretec Oy are €−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Bioretec Oy (BRETEC)?
The return on equity (ROE) of Bioretec Oy is −4,861% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bioretec Oy (BRETEC)?
On an EBIT basis the return on assets of Bioretec Oy is −47.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Bioretec Oy (BRETEC) generate?
The free cash flow of Bioretec Oy is −€10.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bioretec Oy (BRETEC) carry?
The net debt of Bioretec Oy is €506K (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bioretec Oy in the live analysis
One click puts Bioretec Oy on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
